Company Genome & Company

Equities

A314130

KR7314130006

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6,910 ^KRW	+2.98%		-1.71%	-44.68%

Jan. 24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

Genome&Company is a company mainly engaged in the research, development, manufacturing and sale of probiotics. Probiotics are mainly used in products including immune oncology therapeutic supplements, dietary supplements, cosmetics and medicines. These products are mainly applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies.

KRW in Million	2022	Weight	2023	Weight	Delta
Service 55.0 %	7,408	52.6 %	7,857	55.0 %	+6.06%
Immuno-cancer Drugs - Product 43.5 %	6,462	45.9 %	6,212	43.5 %	-3.87%
Usage Fee 1.5 %	212	1.5 %	212	1.5 %	-0.13%
Immuno-cancer Drugs - Merchandise 0.1 %	3	0.0 %	16	0.1 %	+496.15%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	14,085	100.0 %	14,296	100.0 %	+1.50%

Managers	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	51	15-09-23
Ji-Soo Bae FOU	Founder	53	15-09-23
Young-Jin Seo BRD	Director/Board Member	44	-
Byung-Gyu Park IRC	Investor Relations Contact	44	-
Se-Hyun Jung AUD	Comptroller/Controller/Auditor	50	-

Members of the board	Title	Age	Since
Byeong-Geon Lee BRD	Director/Board Member	67	-
Ji-Soo Bae FOU	Founder	53	15-09-23
Han-Su Park CEO	Chief Executive Officer	51	15-09-23
Young-Jin Seo BRD	Director/Board Member	44	-
Jung-Wook Seo BRD	Director/Board Member	62	19-06-13
Gwang-Min Nam BRD	Director/Board Member	44	-

	Vote	Quantity	Free-Float	Total Float
Stock A	0	946,591	0	65.47 %
Stock B	0	493,180	0
Stock C	1	14,974,158	9,803,896 ( 65.47 %)

Name	Equities	%	Valuation
Han-Su Park 11.38 %	1,703,380	11.38 %	12 M ₩
Ji-Soo Bae 10.52 %	1,575,320	10.52 %	11 M ₩
InterVest Co., Ltd. 5.459 %	817,438	5.459 %	6 M ₩
Korea Investment Partners Co., Ltd. 5.389 %	807,000	5.389 %	5 M ₩
DSC Investment, Inc. (Venture Capital) 5.365 %	803,390	5.365 %	5 M ₩
Seok Hong Yoo 3.234 %	484,230	3.234 %	3 M ₩
Genome & Co. ESOA 0.7359 %	110,202	0.7359 %	749 006 ₩
DONGKOO BIO & PHARMA CO., LTD. 0.6678 %	100,000	0.6678 %	679 666 ₩
Kyung-mi Park 0.000000 %	0	0.000000 %	- ₩

Genome & Co.

8/F, Pangyo Valley B 35 Pangyo-ro 255beon-gil

13486, Seongnam-si

http://www.genomecom.co.kr

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOME & COMPANY	-44.68%	73.04M
IQVIA HOLDINGS INC.	+0.53%	42.86B
MODERNA, INC.	+12.13%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.78%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.64%	18.63B
MEDPACE HOLDINGS, INC.	+27.68%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.56%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.83%	11.21B

Other Biotechnology & Medical Research